CRISPR–Cas12a was used to directly replace mouse antibody variable chain genes with human versions in primary B cells. The edited cells underwent affinity maturation in vivo, improving the potency of HIV-1 and SARS-CoV-2 neutralizing antibodies without loss of bioavailability. Affinity maturation of edited cells also enables new vaccine models and adaptive B cell therapies.

中文翻译：

---

CRISPR 改造的 B 细胞受体体内亲和力成熟

CRISPR-Cas12a 用于在原代 B 细胞中直接用人源版本替换小鼠抗体可变链基因。编辑后的细胞在体内经历了亲和力成熟，提高了 HIV-1 和 SARS-CoV-2 中和抗体的效力，且不损失生物利用度。编辑细胞的亲和力成熟还使得新的疫苗模型和适应性 B 细胞疗法成为可能。